Oriza Seed Capital (Oriza Yuandian)
84
17M
64
7.64
12
0.24
5
- Areas of investment
Summary
The venture was found in Asia in China. The leading representative office of defined VC is situated in the Suzhou.
The important activity for fund was in 2019. The higher amount of exits for fund were in 2019. The fund is constantly included in 2-6 deals per year. The average startup value when the investment from Oriza Seed Capital (Oriza Yuandian) is 500 millions - 1 billion dollars. Opposing the other organizations, this Oriza Seed Capital (Oriza Yuandian) works on 22 percentage points less the average amount of lead investments. Considering the real fund results, this VC is 16 percentage points more often commits exit comparing to other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund.
The overall number of key employees were 2.
We can highlight the next thriving fund investment areas, such as Biopharma, Health Care. Among the most popular portfolio startups of the fund, we may highlight Cambricon, CStone Pharmaceuticals, JW Therapeutics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. The fund has exact preference in some founders of portfolio startups. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Oriza Seed Capital (Oriza Yuandian), startups are often financed by YuanMing Capital, Yonghua Capital, WuXi Healthcare Ventures. The meaningful sponsors for the fund in investment in the same round are YuanMing Capital, Yonghua Capital, TF Capital. In the next rounds fund is usually obtained by YuanMing Capital, SDIC Venture Capital, Yonghua Capital.
Investments analytics
Analytics
- Total investments
- 84
- Lead investments
- 12
- Exits
- 5
- Rounds per year
- 7.64
- Follow on index
- 0.24
- Investments by industry
- Manufacturing (25)
- Health Care (18)
- Biotechnology (12)
- Medical (11)
- Industrial Automation (9) Show 95 more
- Investments by region
-
- China (78)
- United States (4)
- Peak activity year
- 2019
- Number of Unicorns
- 2
- Number of Decacorns
- 2
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Avg. valuation at time of investment
- 76M
- Group Appearance index
- 0.87
- Strategy success index
- 0.30
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Eccogene | 12 Jun 2023 | Health Care | Early Stage Venture | 27M | Shanghai, China |
| Juncell Therapeutics | 15 Jan 2022 | Early Stage Venture | Shanghai, Jiading, China |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.